SU1450746A3 - Способ получени производных 1,3-дигидро-2Н-имидазо/4,5-в/хинолин-2-онов или их фармацевтически приемлемых солей - Google Patents

Способ получени производных 1,3-дигидро-2Н-имидазо/4,5-в/хинолин-2-онов или их фармацевтически приемлемых солей Download PDF

Info

Publication number: SU1450746A3
Authority: SU; USSR - Soviet Union
Prior art keywords: singlet; hydrogen; imidazo; dihydro; halogen
Prior art date: 1985-04-25

Application number

SU864027355A

Other languages

English (en)

Russian (ru)

Inventor

А.Минвел Николас

Дж.Райт Джон

Original Assignee

Бристоль-Мейерз Компани (Фирма)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-04-25

Filing date

1986-04-24

Publication date

1989-01-07

1986-04-24 Application filed by Бристоль-Мейерз Компани (Фирма) filed Critical Бристоль-Мейерз Компани (Фирма)

1989-01-07 Application granted granted Critical

1989-01-07 Publication of SU1450746A3 publication Critical patent/SU1450746A3/ru

Links

238000000034 method Methods 0.000 title claims description 7
150000003839 salts Chemical class 0.000 title claims description 3
BINWKEIURMBREF-UHFFFAOYSA-N 1,3-dihydroimidazo[4,5-b]quinolin-2-one Chemical class C1=CC=C2N=C(NC(=O)N3)C3=CC2=C1 BINWKEIURMBREF-UHFFFAOYSA-N 0.000 title abstract 2
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 23
239000001257 hydrogen Substances 0.000 claims abstract description 20
150000002431 hydrogen Chemical group 0.000 claims abstract description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 5
125000000217 alkyl group Chemical group 0.000 claims abstract 10
125000003545 alkoxy group Chemical group 0.000 claims abstract 9
229910052736 halogen Inorganic materials 0.000 claims abstract 9
150000002367 halogens Chemical group 0.000 claims abstract 9
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 10
230000005764 inhibitory process Effects 0.000 claims description 10
230000008602 contraction Effects 0.000 claims description 8
229940091173 hydantoin Drugs 0.000 claims description 2
150000001469 hydantoins Chemical class 0.000 claims description 2
235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
239000007800 oxidant agent Substances 0.000 claims 1
238000011084 recovery Methods 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 35
210000001772 blood platelet Anatomy 0.000 abstract description 13
208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 11
239000003112 inhibitor Substances 0.000 abstract description 4
239000000496 cardiotonic agent Substances 0.000 abstract description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
125000003118 aryl group Chemical group 0.000 description 30
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
239000007787 solid Substances 0.000 description 19
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 18
239000000203 mixture Substances 0.000 description 17
238000012360 testing method Methods 0.000 description 15
-1 5-Fluoro-2-nitrophenyl Chemical group 0.000 description 14
238000010992 reflux Methods 0.000 description 14
238000009835 boiling Methods 0.000 description 13
239000002904 solvent Substances 0.000 description 13
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 12
239000011630 iodine Substances 0.000 description 12
229910052740 iodine Inorganic materials 0.000 description 12
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 12
235000019345 sodium thiosulphate Nutrition 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
239000011541 reaction mixture Substances 0.000 description 10
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
229910000029 sodium carbonate Inorganic materials 0.000 description 9
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 8
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 7
230000002776 aggregation Effects 0.000 description 7
238000004220 aggregation Methods 0.000 description 7
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 7
239000002689 soil Substances 0.000 description 7
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
230000000297 inotrophic effect Effects 0.000 description 6
229910052763 palladium Inorganic materials 0.000 description 6
239000000126 substance Substances 0.000 description 6
ODCKPUDNMNCWMR-UHFFFAOYSA-N 7,8-dimethyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one Chemical compound N1=C2NC(=O)NC2=CC2=C(C)C(C)=CC=C21 ODCKPUDNMNCWMR-UHFFFAOYSA-N 0.000 description 5
208000007536 Thrombosis Diseases 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000004044 response Effects 0.000 description 5
WPNOABJRAVXWKU-UHFFFAOYSA-N 7-methoxy-1,3-dihydroimidazo[4,5-b]quinolin-2-one Chemical compound N1=C2NC(=O)NC2=CC2=CC(OC)=CC=C21 WPNOABJRAVXWKU-UHFFFAOYSA-N 0.000 description 4
102000008186 Collagen Human genes 0.000 description 4
108010035532 Collagen Proteins 0.000 description 4
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 4
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000003610 charcoal Substances 0.000 description 4
229920001436 collagen Polymers 0.000 description 4
238000002425 crystallisation Methods 0.000 description 4
230000008025 crystallization Effects 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
WJRBRSLFGCUECM-UHFFFAOYSA-N CH2-hydantoin Natural products O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
241000282339 Mustela Species 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
239000003245 coal Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical class O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
230000002107 myocardial effect Effects 0.000 description 3
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
210000004623 platelet-rich plasma Anatomy 0.000 description 3
230000002265 prevention Effects 0.000 description 3
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
VZXBGYRONYENIL-UHFFFAOYSA-N 8-chloro-1,3-dihydroimidazo[4,5-b]quinolin-2-one Chemical compound C1=C2C(Cl)=CC=CC2=NC2=C1NC(=O)N2 VZXBGYRONYENIL-UHFFFAOYSA-N 0.000 description 2
208000005189 Embolism Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
RHYBFKMFHLPQPH-UHFFFAOYSA-N N-methylhydantoin Chemical compound CN1CC(=O)NC1=O RHYBFKMFHLPQPH-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
208000001435 Thromboembolism Diseases 0.000 description 2
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
239000000538 analytical sample Substances 0.000 description 2
230000002965 anti-thrombogenic effect Effects 0.000 description 2
230000001746 atrial effect Effects 0.000 description 2
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000002057 chronotropic effect Effects 0.000 description 2
229940095074 cyclic amp Drugs 0.000 description 2
229940113088 dimethylacetamide Drugs 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
210000002837 heart atrium Anatomy 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000000691 measurement method Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
230000009090 positive inotropic effect Effects 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
210000005245 right atrium Anatomy 0.000 description 2
210000005241 right ventricle Anatomy 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
PJRUEHQERHHYKI-UHFFFAOYSA-N 1,7,8-trimethyl-3h-imidazo[4,5-b]quinolin-2-one Chemical compound N1=C2NC(=O)N(C)C2=CC2=C(C)C(C)=CC=C21 PJRUEHQERHHYKI-UHFFFAOYSA-N 0.000 description 1
OGGMUYJRABMJGV-UHFFFAOYSA-N 1,7-dimethyl-3h-imidazo[4,5-b]quinolin-2-one Chemical compound N1=C2NC(=O)N(C)C2=CC2=CC(C)=CC=C21 OGGMUYJRABMJGV-UHFFFAOYSA-N 0.000 description 1
YEZYOQWGSQOGIH-UHFFFAOYSA-N 1,8-dimethyl-3h-imidazo[4,5-b]quinolin-2-one Chemical compound C1=C2C(C)=CC=CC2=NC2=C1N(C)C(=O)N2 YEZYOQWGSQOGIH-UHFFFAOYSA-N 0.000 description 1
AUDZMEBVHMNUTQ-UHFFFAOYSA-N 1-methyl-5-methylideneimidazolidine-2,4-dione Chemical compound CN1C(=C)C(=O)NC1=O AUDZMEBVHMNUTQ-UHFFFAOYSA-N 0.000 description 1
125000002124 5'-adenosyl group Chemical group N1=CN=C2N(C=NC2=C1N)[C@H]1[C@H](O)[C@H](O)[C@H](O1)C* 0.000 description 1
UJIBFPBOBFXMKO-UHFFFAOYSA-N 5-methylideneimidazolidine-2,4-dione Chemical compound C=C1NC(=O)NC1=O UJIBFPBOBFXMKO-UHFFFAOYSA-N 0.000 description 1
AMQUYLNSYUJEKH-UHFFFAOYSA-N 6,7,8-trimethoxy-1,3-dihydroimidazo[4,5-b]quinolin-2-one Chemical compound C1=C2C(OC)=C(OC)C(OC)=CC2=NC2=C1NC(=O)N2 AMQUYLNSYUJEKH-UHFFFAOYSA-N 0.000 description 1
VBQVHGPNYUAGFI-UHFFFAOYSA-N 6,7-dimethyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one Chemical compound N1=C2C=C(C)C(C)=CC2=CC2=C1NC(=O)N2 VBQVHGPNYUAGFI-UHFFFAOYSA-N 0.000 description 1
KOPBXGWUOMDXIW-UHFFFAOYSA-N 7-chloro-6-methyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one Chemical compound C1=C2C=C(Cl)C(C)=CC2=NC2=C1NC(=O)N2 KOPBXGWUOMDXIW-UHFFFAOYSA-N 0.000 description 1
BSAKVJKPJIQKNP-UHFFFAOYSA-N 7-methyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one Chemical compound N1=C2NC(=O)NC2=CC2=CC(C)=CC=C21 BSAKVJKPJIQKNP-UHFFFAOYSA-N 0.000 description 1
241001290610 Abildgaardia Species 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
SHFVLEBSLCOYPS-UHFFFAOYSA-N CC(C=CC=C1[N+]([O-])=O)=C1N(C(C(N1)=O)=C)C1=O Chemical compound CC(C=CC=C1[N+]([O-])=O)=C1N(C(C(N1)=O)=C)C1=O SHFVLEBSLCOYPS-UHFFFAOYSA-N 0.000 description 1
241000700198 Cavia Species 0.000 description 1
206010008132 Cerebral thrombosis Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010011091 Coronary artery thrombosis Diseases 0.000 description 1
201000001429 Intracranial Thrombosis Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
YWDRNRWOQCAZFB-UHFFFAOYSA-N O.CC=1C=2C=C3C(=NC2C=CC1)NC(N3)=O Chemical compound O.CC=1C=2C=C3C(=NC2C=CC1)NC(N3)=O YWDRNRWOQCAZFB-UHFFFAOYSA-N 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
241000700159 Rattus Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
238000004026 adhesive bonding Methods 0.000 description 1
238000010009 beating Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
150000001804 chlorine Chemical class 0.000 description 1
208000002528 coronary thrombosis Diseases 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
ORPJQSFBLBHKPN-UHFFFAOYSA-N dichloromethane;methylsulfinylmethane Chemical compound ClCCl.CS(C)=O ORPJQSFBLBHKPN-UHFFFAOYSA-N 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
201000005577 familial hyperlipidemia Diseases 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
PZVFRCCIJOLDRB-UHFFFAOYSA-N imidazo[4,5-b]quinolin-2-one Chemical compound C1=CC=CC2=NC3=NC(=O)N=C3C=C21 PZVFRCCIJOLDRB-UHFFFAOYSA-N 0.000 description 1
HOPZBJPSUKPLDT-UHFFFAOYSA-N imidazo[4,5-h]quinolin-2-one Chemical class C1=CN=C2C3=NC(=O)N=C3C=CC2=C1 HOPZBJPSUKPLDT-UHFFFAOYSA-N 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
210000005246 left atrium Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229960003574 milrinone Drugs 0.000 description 1
PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
230000008288 physiological mechanism Effects 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
201000005060 thrombophlebitis Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
230000002792 vascular Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SU864027355A 1985-04-25 1986-04-24 Способ получени производных 1,3-дигидро-2Н-имидазо/4,5-в/хинолин-2-онов или их фармацевтически приемлемых солей SU1450746A3 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72686985A	1985-04-25	1985-04-25
US06/832,212 US4668686A (en)	1985-04-25	1986-02-26	Imidazoquinoline antithrombrogenic cardiotonic agents

Publications (1)

Publication Number	Publication Date
SU1450746A3 true SU1450746A3 (ru)	1989-01-07

Family

ID=27111398

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SU864027355A SU1450746A3 (ru)	1985-04-25	1986-04-24	Способ получени производных 1,3-дигидро-2Н-имидазо/4,5-в/хинолин-2-онов или их фармацевтически приемлемых солей
SU874202071A SU1470192A3 (ru)	1985-04-25	1987-02-27	Способ получени имидазохинолиновых соединений или их фармацевтически приемлемых солей
SU874203391A SU1560056A3 (ru)	1985-04-25	1987-09-25	Способ получени производных 1,3,9,9 @ -тетрагидро-2Н-имидазо [4,5- @ ]хинолин-2-она или их фармацевтически приемлемых солей

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SU874202071A SU1470192A3 (ru)	1985-04-25	1987-02-27	Способ получени имидазохинолиновых соединений или их фармацевтически приемлемых солей
SU874203391A SU1560056A3 (ru)	1985-04-25	1987-09-25	Способ получени производных 1,3,9,9 @ -тетрагидро-2Н-имидазо [4,5- @ ]хинолин-2-она или их фармацевтически приемлемых солей

Country Status (32)

Country	Link
US (1)	US4668686A (2)
KR (1)	KR940000828B1 (2)
CN (1)	CN1016175B (2)
AT (1)	AT390257B (2)
AU (1)	AU592983B2 (2)
BE (1)	BE904671A (2)
CA (1)	CA1298836C (2)
CH (1)	CH675722A5 (2)
CY (1)	CY1641A (2)
DE (1)	DE3614132A1 (2)
DK (3)	DK164868C (2)
EG (1)	EG18104A (2)
ES (3)	ES8708229A1 (2)
FI (1)	FI83316C (2)
FR (1)	FR2581065B1 (2)
GB (1)	GB2174987B (2)
GR (1)	GR861086B (2)
HK (1)	HK64492A (2)
HU (1)	HU195813B (2)
IL (1)	IL78581A0 (2)
IT (1)	IT1215651B (2)
LU (1)	LU86406A1 (2)
MY (1)	MY102086A (2)
NL (1)	NL8601053A (2)
NO (1)	NO163406C (2)
NZ (1)	NZ215885A (2)
OA (1)	OA08242A (2)
PT (1)	PT82460B (2)
SE (1)	SE461468B (2)
SG (1)	SG29092G (2)
SU (3)	SU1450746A3 (2)
YU (1)	YU46054B (2)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2131876C1 (ru) *	1993-07-06	1999-06-20	Пфайзер Инк.	Бициклические тетрагидропиразолпиридины или их фармацевтически приемлемые соли, фармацевтическая композиция, способ ингибирования фосфодиэстеразы, способ лечения
RU2304143C2 (ru) *	2001-12-06	2007-08-10	3М Инновейтив Пропертиз Компани	Тиоэфирзамещенные имидазохинолины и фармацевтическая композиция на их основе
RU2412942C2 (ru) *	2003-10-03	2011-02-27	3М Инновейтив Пропертиз Компани	Оксизамещенные имидазохинолины, способные модулировать биосинтез цитокинов
RU2415857C2 (ru) *	2004-09-14	2011-04-10	Новартис Вэксинс Энд Диагностикс Инк.	Имидазохинолиновые соединения

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4775674A (en) *	1986-05-23	1988-10-04	Bristol-Myers Company	Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4701459A (en) *	1986-07-08	1987-10-20	Bristol-Myers Company	7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US4743607A (en) *	1987-05-29	1988-05-10	Merrell Dow Pharmaceuticals Inc.	Cardiotonic tricyclic imidazolones
US4803210A (en) *	1987-05-29	1989-02-07	Merrell Dow Pharmaceuticals Inc.	Cardiotonic tricyclic oxazolones
US4943573A (en) *	1989-11-01	1990-07-24	Bristol-Myers Squibb Company	Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
DE4035854C2 (de) *	1990-11-10	1996-10-02	Daimler Benz Ag	Vorrichtung zum Fangen und Ableiten des von einem Fahrzeugrad hochgeschleuderten Spritzwassers
PH31245A (en) *	1991-10-30	1998-06-18	Janssen Pharmaceutica Nv	1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5208237A (en) *	1992-04-03	1993-05-04	Bristol-Meyers Squibb Company	7-oxypropylsulfonamido-imidazo[4,5-b]quinolin-2-ones
US5196428A (en) *	1992-04-03	1993-03-23	Bristol-Myers Squibb Company	Imidazo[4,5-b]qinolinyl oxy alkyl ureas
US5158958A (en) *	1992-04-03	1992-10-27	Bristol-Myers Squibb Company	Imidazo[4,5-b]quinolinyl oxy alkyl sulfonyl piperidine derivatives
US5348960A (en) *	1992-04-03	1994-09-20	Bristol-Myers Squibb Company	Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivatives
US5552267A (en) *	1992-04-03	1996-09-03	The Trustees Of Columbia University In The City Of New York	Solution for prolonged organ preservation
TW593317B (en) *	1993-06-21	2004-06-21	Janssen Pharmaceutica Nv	Positive cardiac inotropic and lusitropic pyrroloquinolinone derivatives
TW574214B (en) *	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
MXPA06001669A (es)	2003-08-12	2006-04-28	3M Innovative Properties Co	Compuestos que contienen imidazo-oxima sustituidos.
NZ545412A (en)	2003-08-27	2008-12-24	Coley Pharm Group Inc	Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504269A (ja)	2003-09-05	2007-03-01	スリーエムイノベイティブプロパティズカンパニー	Ｃｄ５＋ｂ細胞リンパ腫の治療方法
US7544697B2 (en)	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
CN1906192A (zh) *	2003-11-14	2007-01-31	3M创新有限公司	羟胺取代的咪唑环化合物
WO2005048933A2 (en)	2003-11-14	2005-06-02	3M Innovative Properties Company	Oxime substituted imidazo ring compounds
AU2004293078B2 (en)	2003-11-25	2012-01-19	3M Innovative Properties Company	Substituted imidazo ring systems and methods
JP2007517035A (ja)	2003-12-29	2007-06-28	スリーエムイノベイティブプロパティズカンパニー	アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
EP1699788A2 (en)	2003-12-30	2006-09-13	3M Innovative Properties Company	Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
US8697873B2 (en)	2004-03-24	2014-04-15	3M Innovative Properties Company	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en)	2004-06-15	2011-09-13	3M Innovative Properties Company	Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009826A1 (en)	2004-06-18	2006-01-26	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (en)	2004-06-18	2006-04-13	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
US7915281B2 (en)	2004-06-18	2011-03-29	3M Innovative Properties Company	Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
JP5313502B2 (ja)	2004-12-30	2013-10-09	スリーエムイノベイティブプロパティズカンパニー	置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
CA2592904C (en)	2004-12-30	2015-04-07	3M Innovative Properties Company	Chiral fused [1,2]imidazo[4,5-c] ring compounds
JP2008530022A (ja)	2005-02-04	2008-08-07	コーリーファーマシューティカルグループ，インコーポレイテッド	免疫反応調節物質を含む水性ゲル処方物
EP1846405A2 (en)	2005-02-11	2007-10-24	3M Innovative Properties Company	Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
CA2602683A1 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	Pyrazolopyridine-1,4-diamines and analogs thereof
CA2602590A1 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
WO2008008432A2 (en)	2006-07-12	2008-01-17	Coley Pharmaceutical Group, Inc.	Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
US8227603B2 (en)	2006-08-01	2012-07-24	Cytokinetics, Inc.	Modulating skeletal muscle
US8299248B2 (en)	2006-08-02	2012-10-30	Cytokinetics, Incorporated	Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
DK2069352T5 (en)	2006-08-02	2017-04-03	Cytokinetics Inc	SPECIFIC CHEMICAL UNITS, COMPOSITIONS AND PROCEDURES
EP2139478A4 (en) *	2007-03-30	2010-05-05	Cytokinetics Inc	CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
US10272082B2 (en)	2011-07-13	2019-04-30	Cytokinetics, Inc.	Combination ALS therapy
WO2024149378A1 (zh) *	2023-01-13	2024-07-18	上海超阳药业有限公司	喹啉酮化合物和萘啶酮化合物及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3932407A (en) *	1973-11-19	1976-01-13	Bristol-Myers Company	Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones

1986
- 1986-02-26 US US06/832,212 patent/US4668686A/en not_active Expired - Fee Related
- 1986-03-26 CA CA000505136A patent/CA1298836C/en not_active Expired - Fee Related
- 1986-04-18 NZ NZ215885A patent/NZ215885A/xx unknown
- 1986-04-21 AU AU56413/86A patent/AU592983B2/en not_active Ceased
- 1986-04-22 FI FI861684A patent/FI83316C/fi not_active IP Right Cessation
- 1986-04-22 IL IL78581A patent/IL78581A0/xx not_active IP Right Cessation
- 1986-04-23 CN CN86102747A patent/CN1016175B/zh not_active Expired
- 1986-04-23 EG EG237/86A patent/EG18104A/xx active
- 1986-04-24 BE BE0/216585A patent/BE904671A/fr not_active IP Right Cessation
- 1986-04-24 IT IT8620206A patent/IT1215651B/it active
- 1986-04-24 SU SU864027355A patent/SU1450746A3/ru active
- 1986-04-24 GB GB8610037A patent/GB2174987B/en not_active Expired
- 1986-04-24 ES ES554336A patent/ES8708229A1/es not_active Expired
- 1986-04-24 PT PT82460A patent/PT82460B/pt not_active IP Right Cessation
- 1986-04-24 NL NL8601053A patent/NL8601053A/xx not_active Application Discontinuation
- 1986-04-24 NO NO861617A patent/NO163406C/no unknown
- 1986-04-24 CH CH1679/86A patent/CH675722A5/de not_active IP Right Cessation
- 1986-04-24 GR GR861086A patent/GR861086B/el unknown
- 1986-04-24 DK DK190986A patent/DK164868C/da not_active IP Right Cessation
- 1986-04-24 SE SE8601907A patent/SE461468B/sv not_active IP Right Cessation
- 1986-04-24 FR FR868605966A patent/FR2581065B1/fr not_active Expired - Fee Related
- 1986-04-24 LU LU86406A patent/LU86406A1/fr unknown
- 1986-04-25 KR KR1019860003204A patent/KR940000828B1/ko not_active Expired - Lifetime
- 1986-04-25 OA OA58845A patent/OA08242A/xx unknown
- 1986-04-25 HU HU861723A patent/HU195813B/hu not_active IP Right Cessation
- 1986-04-25 AT AT0112186A patent/AT390257B/de not_active IP Right Cessation
- 1986-04-25 DE DE19863614132 patent/DE3614132A1/de not_active Ceased
1987
- 1987-02-27 SU SU874202071A patent/SU1470192A3/ru active
- 1987-05-14 ES ES557552A patent/ES8802521A1/es not_active Expired
- 1987-05-14 ES ES557551A patent/ES8801829A1/es not_active Expired
- 1987-06-23 YU YU116787A patent/YU46054B/sh unknown
- 1987-09-25 SU SU874203391A patent/SU1560056A3/ru active
- 1987-09-29 MY MYPI87002266A patent/MY102086A/en unknown
1991
- 1991-04-30 DK DK080291A patent/DK165248C/da not_active IP Right Cessation
- 1991-05-01 DK DK081091A patent/DK165249C/da not_active IP Right Cessation
1992
- 1992-03-10 SG SG290/92A patent/SG29092G/en unknown
- 1992-08-27 HK HK644/92A patent/HK64492A/xx unknown
- 1992-11-06 CY CY1641A patent/CY1641A/en unknown

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kozak, et al., Bull. Intern. Acaol. Polanaise, 1930, A 432-438 (Chem. Abs., 25, 5400). *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2131876C1 (ru) *	1993-07-06	1999-06-20	Пфайзер Инк.	Бициклические тетрагидропиразолпиридины или их фармацевтически приемлемые соли, фармацевтическая композиция, способ ингибирования фосфодиэстеразы, способ лечения
RU2304143C2 (ru) *	2001-12-06	2007-08-10	3М Инновейтив Пропертиз Компани	Тиоэфирзамещенные имидазохинолины и фармацевтическая композиция на их основе
RU2412942C2 (ru) *	2003-10-03	2011-02-27	3М Инновейтив Пропертиз Компани	Оксизамещенные имидазохинолины, способные модулировать биосинтез цитокинов
RU2415857C2 (ru) *	2004-09-14	2011-04-10	Новартис Вэксинс Энд Диагностикс Инк.	Имидазохинолиновые соединения

Also Published As

Publication number	Publication date
FI861684A0 (fi)	1986-04-22
FI83316B (fi)	1991-03-15
DK80291A (da)	1991-04-30
PT82460B (pt)	1988-11-30
ES554336A0 (es)	1987-10-01
BE904671A (fr)	1986-10-24
DK165248C (da)	1993-03-22
DK81091A (da)	1991-05-01
DK165248B (da)	1992-10-26
YU116787A (en)	1988-04-30
FI83316C (fi)	1991-06-25
AU592983B2 (en)	1990-02-01
EG18104A (en)	1992-09-30
DK190986A (da)	1986-10-26
ES8801829A1 (es)	1988-02-16
NZ215885A (en)	1989-04-26
AU5641386A (en)	1986-10-30
KR860008177A (ko)	1986-11-12
CN1016175B (zh)	1992-04-08
SG29092G (en)	1992-05-15
GR861086B (en)	1986-09-01
MY102086A (en)	1992-03-31
ES8802521A1 (es)	1988-07-16
IT1215651B (it)	1990-02-22
SE461468B (sv)	1990-02-19
FR2581065A1 (fr)	1986-10-31
OA08242A (en)	1987-10-30
DK80291D0 (da)	1991-04-30
NL8601053A (nl)	1986-11-17
FR2581065B1 (fr)	1990-02-02
IL78581A0 (en)	1986-08-31
AT390257B (de)	1990-04-10
CN86102747A (zh)	1987-02-04
SE8601907L (sv)	1986-10-26
YU46054B (sh)	1992-12-21
DK190986D0 (da)	1986-04-24
CY1641A (en)	1992-11-06
ES557552A0 (es)	1988-07-16
DK165249C (da)	1993-03-22
GB8610037D0 (en)	1986-05-29
PT82460A (en)	1986-05-01
HK64492A (en)	1992-09-04
HU195813B (en)	1988-07-28
LU86406A1 (fr)	1986-11-05
DK164868B (da)	1992-08-31
FI861684L (fi)	1986-10-26
US4668686A (en)	1987-05-26
ATA112186A (de)	1989-09-15
ES8708229A1 (es)	1987-10-01
SE8601907D0 (sv)	1986-04-24
SU1560056A3 (ru)	1990-04-23
IT8620206A0 (it)	1986-04-24
CA1298836C (en)	1992-04-14
CH675722A5 (2)	1990-10-31
NO163406C (no)	1990-05-23
NO861617L (no)	1986-10-27
HUT42089A (en)	1987-06-29
DE3614132A1 (de)	1986-11-27
DK81091D0 (da)	1991-05-01
DK164868C (da)	1993-01-11
ES557551A0 (es)	1988-02-16
KR940000828B1 (ko)	1994-02-02
NO163406B (no)	1990-02-12
SU1470192A3 (ru)	1989-03-30
DK165249B (da)	1992-10-26
GB2174987A (en)	1986-11-19
GB2174987B (en)	1989-08-02

Publication	Publication Date	Title
KR940000828B1 (ko)	1994-02-02	항혈전성 강심제 이미다조 퀴놀린의 제조방법
US4256748A (en)	1981-03-17	Imidazo[2,1-b]quinazolin-2(3H)-ones and pharmaceutical compositions for treatment and prophylaxis of cardiac insufficiency and cardiac failure
KR100885308B1 (ko)	2009-02-24	５－ｈｔ6 및／또는 ５－ｈｔ7 세로토닌 수용체의리간드로서 사용되는 ５－할로-트립타민 유도체
CH639847A5 (it)	1983-12-15	Cicloalchiltriazoli.
Monge et al.	1987	Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino [4, 5-b] indole, 4-hydrazinotriazino [4, 5-a] indole, and related compounds
PT87051B (pt)	1992-07-31	Processo para a preparacao de agentes anti-arritmicos de indano-sulfonamidas
SU1238732A3 (ru)	1986-06-15	Способ получени 6-хлор-3-метил-2,3,4,5-тетрагидро-1 @ -3-бензазепина или его гидрохлорида
KR100661774B1 (ko)	2006-12-28	광학적 활성 피리딜-4에이치-1,2,4-옥사디아진 유도체 및이것의 혈관 질환의 치료에서의 용도
JPH02180A (ja)	1990-01-05	２，２‐ジメチルクロメン誘導体、その製造方法及びこれを含む薬剤組成物
RU2129554C1 (ru)	1999-04-27	Производные пирролхинолинона, способ их получения, промежуточные соединения для их получения, фармацевтический состав и способ его получения
NO780050L (no)	1978-07-10	Fremgangsmaate ved fremstilling av 4,5,6,7-tetrahydrothieno-(2,3-c) og (3,2-c)pyridiner
NZ207981A (en)	1987-05-29	Pyrimidones and pharmaceutical compositions
NO801843L (no)	1980-12-22	Nye kinazolinderivater og farmasoeytiske preparater
PT87050B (pt)	1992-07-31	Processo para a preparacao de agentes anti-arritmicos de indano-sulfonamidas
JPS5953493A (ja)	1984-03-28	新規なチエノ−チアゾ−ル誘導体
SU1500160A3 (ru)	1989-08-07	Способ получени производных пиперазин-1-ил-эрголина
JPH04230285A (ja)	1992-08-19	利尿作用を有する医薬品およびその製造方法ならびに新規の３，７−ジアザビシクロ〔３．３．１〕ノナン化合物およびその製造方法
PT87049B (pt)	1992-07-31	Processo para a preparacao de agentes anti-arritmicos de benzazepino-sulfonamidas
JPH05506654A (ja)	1993-09-30	１，５―ベンゾチアゼピノン誘導体、その製法および医薬品用途
AU619049B2 (en)	1992-01-16	New 1,4-dihydropyridinederivative, namely (-)-2-{(2- aminoethoxy) ethoxy)-4-(2,3-dichlorophenyl)-3- ethoxycarbonyl-50methoxycarbonyl-6-methyl}-1,4- dihydropyridine, process for preparing it and pharmaceutical compositions containing it
US4224335A (en)	1980-09-23	Tetrahydrocarbazoles and their use
HU196308B (en)	1988-11-28	Process for producing pharmaceutical compositions containing 2-methyl-thiazolo/4,5-c/quinoline as active component
RU1838313C (ru)	1993-08-30	Способ получени спиросоединени азолона или его N-оксидного производного или его основной соли с фармакологически применимым катионом
SU1241993A3 (ru)	1986-06-30	Способ получени бициклических соединений или их гидрохлоридов
EP0312245A2 (en)	1989-04-19	Polycyclic compounds and pharmaceutical compositions thereof

SU1450746A3 - Способ получени производных 1,3-дигидро-2Н-имидазо/4,5-в/хинолин-2-онов или их фармацевтически приемлемых солей - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=27111398

Family Applications (3)

Family Applications After (2)

Country Status (32)

Cited By (4)

Families Citing this family (41)

Family Cites Families (1)

Non-Patent Citations (1)

Cited By (4)

Also Published As

Similar Documents